Any patient who is taking the medication should be aware of the Onglyza FDA warning and the associated side effects.

The Onglyza FDA warning is in place to notify patients and the medical community about the possible serious side effects associated with using this medication.

Unfortunately, a number of different serious medical conditions have been associated with the use of Onglyza, ultimately prompting those harmed patients to take legal action. The prescription drug Onglyza has been linked to possibly fatal heart side effects.

One study identified that patients who take these diabetes medications, including Onglyza and other forms of Saxagliptin, may be at a higher risk of hospitalization associated with heart failure. Patients who have been negatively affected as a result of the side effects named in the Onglyza FDA warning may be eligible to take legal action.

Some of the most common symptoms of heart failure that are explained in the Onglyza FDA warning include weakness, fatigue, unusual shortness of breath during typical activities, tiredness, trouble breathing when lying down, and weight gain with swelling in the legs, ankles, stomach or feet.

Any patient who is experiencing these side effects should consult with a medical professional as soon as possible to determine next steps.

A safety review conducted by the FDA that ultimately led to the Onglyza FDA warning indicates that type-2 diabetes medicines that contain Saxagliptin may increase the risk of heart failure for those patients who already have kidney or heart disease.

These inhibitor drugs are used in combination with exercise and diet in order to decrease blood sugar in adults who have type-2 diabetes. Type-2 diabetes can lead to a number of different serious side effects if untreated, including kidney damage, nerve damage, blindness and heart disease.

Two large clinical trials were conducted in patients with heart disease — the results of which ultimately lead to the Onglyza FDA warning. Each trial shows that those patients who received medicines containing the primary ingredient in Onglyza were hospitalized for heart failure at higher rates when compared with those who received an inactive treatment known as a placebo.

The Onglyza FDA warning may be used to make patients aware of the possible risks. Physicians and pharmaceutical companies are currently in the process of looking for safer alternatives in the treatment of type-2 diabetes. However, there are concerns about serious side effects, especially with the high risk of heart failure, is alarming for many patients who have already been taking the medication for some time and who may have already suffered a serious heart issue.

A study published in the New England Journal of Medicine in 2013, included the experiences of nearly 16,500 patients who were diagnosed with type-2 diabetes. The purpose of the study was to identify which type of type-2 diabetes medications or drugs are right for the patients.

Those patients who took Onglyza were more likely to be hospitalized for heart failure than those who were using other medications. When the heart muscle becomes too weak to pump blood throughout the rest of the body, heart failure can occur. If this situation is not addressed immediately, the person who is affected by it may be at a higher risk of suffering fatal injuries.